Safety Or Efficacy Setback

The main downside risk is that a novel in vivo editing approach produces an adverse safety signal or fails to show convincing target engagement. Because the program is early-stage and company-specific, market effects remain concentrated in Prime and closely related gene-editing peers.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.